Sequana Medical NV
F:2SE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sequana Medical NV
F:2SE
|
BE |
|
Banco Bradesco SA
F:BREA
|
BR |
|
V
|
Viscofan SA
DUS:VIS
|
ES |
|
M
|
Murphy Oil Corp
XBER:MUQ
|
US |
|
R
|
Royal Unibrew A/S
SWB:0R1
|
DK |
|
Aena SME SA
MAD:AENA
|
ES |
|
S
|
Siyaram Silk Mills Ltd
BSE:503811
|
IN |
|
Thunder Power Holdings Inc
OTC:AIEV
|
US |
|
A
|
Alibaba Group Holding Ltd
F:AHLA
|
CN |
Sequana Medical NV
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
